GenMark Diagnostics, Inc. (NASDAQ:GNMK) insider Hany Massarany sold 1,588 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $7.24, for a total value of $11,497.12. Following the sale, the insider now directly owns 371,209 shares in the company, valued at $2,687,553.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hany Massarany also recently made the following trade(s):

  • On Monday, August 21st, Hany Massarany sold 8,311 shares of GenMark Diagnostics stock. The stock was sold at an average price of $9.45, for a total value of $78,538.95.

GenMark Diagnostics, Inc. (GNMK) traded down $3.04 on Friday, hitting $4.26. The stock had a trading volume of 7,007,583 shares, compared to its average volume of 359,599. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.39 and a current ratio of 3.60.

GenMark Diagnostics (NASDAQ:GNMK) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $11.60 million for the quarter, compared to the consensus estimate of $14.56 million. GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 113.51%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.27) EPS. sell-side analysts forecast that GenMark Diagnostics, Inc. will post -1.06 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/genmark-diagnostics-inc-gnmk-insider-hany-massarany-sells-1588-shares/1678944.html.

Several equities research analysts have weighed in on GNMK shares. Canaccord Genuity reissued a “buy” rating and set a $14.00 price objective (down from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. BidaskClub cut GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Needham & Company LLC reissued a “buy” rating and set a $15.00 price objective (down from $17.00) on shares of GenMark Diagnostics in a research note on Wednesday, September 13th. Cowen and Company reissued a “buy” rating and set a $10.00 price objective on shares of GenMark Diagnostics in a research note on Friday. Finally, Raymond James Financial, Inc. reissued a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $12.20.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd bought a new position in shares of GenMark Diagnostics during the second quarter valued at approximately $126,000. Legal & General Group Plc grew its stake in shares of GenMark Diagnostics by 2.1% during the second quarter. Legal & General Group Plc now owns 11,521 shares of the medical equipment provider’s stock valued at $137,000 after buying an additional 240 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of GenMark Diagnostics during the second quarter valued at approximately $137,000. Quantitative Systematic Strategies LLC boosted its holdings in shares of GenMark Diagnostics by 18.4% in the second quarter. Quantitative Systematic Strategies LLC now owns 13,147 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 2,047 shares during the period. Finally, Wrapmanager Inc. purchased a new stake in shares of GenMark Diagnostics in the third quarter valued at approximately $172,000.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.